Logic-Gated Cell Therapies for Unmet Medical Needs
We are developing the Next Generation of Cell Therapies
Our ImmPACT Bio Platforms
Bispecific Chimeric Antigen Receptor (CAR) T cells are designed to address antigen escape
TGF-β CAR rewires T cell responses to soluble factors to overcome the immune suppressive microenvironment in cancer
Bispecific Chimeric Antigen Receptor (CAR) T cells are designed to address antigen escape
Bispecific Chimeric Antigen Receptor (CAR) T cells are designed to address autoimmunity
Bispecific Chimeric Antigen Receptor (CAR) T cells are designed to address autoimmunity
iCAR technology allows specific killing of cancer cells while sparing normal tissue, with potential to treat all solid tumors
TGF-β CAR rewires T cell responses to soluble factors to overcome the immune suppressive microenvironment in cancer.
iCAR technology allows specific killing of cancer cells while sparing normal tissue, with potential to treat all solid tumors.
Co-founded by and Based on the Research of Pioneering Scientists
Meet Our Team
ImmPACT Bio is developing cutting-edge potent and selective CAR T cell technologies to address key biological challenges in treating grievous diseases.
In 2021 ImmPACT Bio merged with Kalthera Therapeutics.
Get to Know Our Technology
ImmPACT Bio is developing logic-gate-based CAR T platforms that address key challenges for current cell therapies in oncology.
Our technologies are designed to prevent antigen escape, to overcome the immunosuppressive tumor environment, and to cure autoimmune disease.
